- 米国企業
- VERTEX PHARMACEUTICALS INC
VERTEX PHARMACEUTICALS INCVRTX
時価総額
$1234.5億
PER
34.1倍
2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
Cash and cash equivalents | 243 | 475 | 489 | 569 | 625 | 715 | 1,184 | 1,665 | 2,650 | 3,109 | 5,988 | 6,795 | 10,504 | 10,369 |
Marketable securities | 788 | 494 | 832 | 896 | 762 | 328 | 251 | 423 | 518 | 699 | 671 | 730 | 275 | 849 |
Accounts receivable, net | 13 | 183 | 143 | 86 | 76 | 178 | 201 | 281 | 410 | 634 | 885 | 1,137 | 1,442 | 1,563 |
Inventories | - | 112 | 30 | 14 | 31 | 57 | 78 | 112 | 124 | 168 | 281 | 353 | 461 | 739 |
Prepaid expenses and other current assets | 13 | 15 | 25 | 24 | 53 | 51 | 71 | 166 | 141 | 214 | 308 | 546 | 554 | 624 |
Total current assets | 1,057 | 1,331 | 1,590 | 1,589 | 1,547 | 1,407 | 1,832 | 2,649 | 3,843 | 4,823 | 8,133 | 9,561 | 13,235 | 14,144 |
Property and equipment, net | - | - | - | - | - | - | - | - | - | - | 959 | 1,094 | 1,108 | 1,159 |
Goodwill | 26 | 31 | 31 | 31 | 40 | 50 | 50 | 50 | 50 | 1,000 | 1,000 | 1,000 | 1,100 | 1,100 |
Other intangible assets, net | - | - | - | - | - | - | - | - | - | 400 | 400 | 400 | 604 | 840 |
Deferred tax assets | - | - | - | - | - | - | - | - | - | 1,191 | 883 | 935 | 1,247 | 1,812 |
Operating lease assets | - | - | - | - | - | - | - | - | - | - | 326 | 330 | 347 | 294 |
Other assets | 17 | 11 | 10 | 2 | 3 | 7 | 12 | 8 | 41 | 158 | 49 | 111 | 522 | 895 |
Long-term marketable securities | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,498 |
Total assets | 1,725 | 2,204 | 2,759 | 2,319 | 2,335 | 2,499 | 2,897 | 3,546 | 6,246 | 8,318 | 11,752 | 13,433 | 18,151 | 22,730 |
Other assets | 17 | 11 | 10 | 2 | 3 | 7 | 12 | 8 | 41 | 158 | 49 | 111 | 522 | 895 |
Total assets | 1,725 | 2,204 | 2,759 | 2,319 | 2,335 | 2,499 | 2,897 | 3,546 | 6,246 | 8,318 | 11,752 | 13,433 | 18,151 | 22,730 |
Accounts payable | 36 | 75 | 101 | 49 | 71 | 75 | 61 | 74 | 111 | 88 | 155 | 195 | 304 | 365 |
Accrued expenses | 134 | 252 | 265 | 271 | 210 | 306 | 315 | 444 | 604 | 1,117 | 1,405 | 1,679 | 2,127 | 2,655 |
Other current liabilities | 6 | - | 20 | 25 | 5 | 14 | 11 | 27 | 41 | 130 | 317 | 268 | 312 | 527 |
Total current liabilities | 475 | 392 | 433 | 398 | 368 | 506 | 793 | 807 | 1,120 | 1,335 | 1,878 | 2,142 | 2,742 | 3,547 |
Long-term finance lease liabilities | - | - | - | - | - | - | - | - | - | 539 | 539 | 510 | 431 | 376 |
Long-term operating lease liabilities | - | - | - | - | - | - | - | - | - | - | 350 | 377 | 380 | 349 |
Other long-term liabilities | - | 7 | 14 | 12 | 22 | 32 | 102 | 26 | 26 | 183 | 108 | 117 | 686 | 878 |
Total liabilities | 1,221 | 1,239 | 1,525 | 963 | 1,238 | 1,405 | 1,559 | 1,504 | 1,811 | 2,233 | 3,065 | 3,333 | 4,238 | 5,150 |
Commitments and contingencies | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Preferred Stock, Value, Issued | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Common Stock, Value, Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Additional paid-in capital | 3,947 | 4,201 | 4,519 | 5,321 | 5,777 | 6,198 | 6,507 | 7,157 | 7,421 | 7,938 | 7,894 | 6,881 | 7,387 | 7,450 |
Accumulated other comprehensive (loss) income | -1 | -1 | -1 | -0 | 1 | 2 | 21 | -12 | 1 | -2 | -68 | 16 | 1 | -14 |
Retained earnings | -3,444 | -3,415 | -3,522 | -3,967 | -4,705 | -5,262 | -5,374 | -5,120 | -2,989 | -1,853 | 859 | 3,201 | 6,523 | 10,142 |
Total shareholders’ equity | 504 | 928 | 1,196 | 1,356 | 1,096 | 1,094 | 1,338 | 2,042 | 4,435 | 6,085 | 8,687 | 10,100 | 13,913 | 17,580 |
Total liabilities and shareholders’ equity | 1,725 | 2,204 | 2,759 | 2,319 | 2,335 | 2,499 | 2,897 | 3,546 | 6,246 | 8,318 | 11,752 | 13,433 | 18,151 | 22,730 |